Rapid Micro reports Q1 growth

Rapid Micro Biosystems reported first-quarter 2026 revenue of $8.0 million, up 11.1% from $7.2 million a year earlier, the company said on May 13. The Lexington, Massachusetts-based company said it placed six new Growth Direct systems in the quarter, compared with three in the first quarter of 2025. (sec.gov) Product revenue rose 36.0% to $5.6 million, while recurring revenue increased 27.7% to $5.1 million and accounted for 63% of total revenue. Rapid Micro reaffirmed its full-year 2026 revenue guidance of $37.0 million to $41.0 million and said it still expects 30 to 38 system placements this year. ### Why did this quarter draw attention beyond the top-line increase? (sec.gov) The six system placements were one of the clearest operating figures in the release. Rapid Micro said first-quarter placements doubled from the prior-year period, even as completed customer validations fell to five from nine. Robert Spignesi, the company’s president and chief executive, said the quarter showed “strong and consistent execution across the business.” He said consumable revenue drove nearly 30% growth in recurring revenue and pointed to “robust customer interest in QC automation” and broader talks with customers about enterprise-level deployments of the Growth Direct platform. (sec.gov) ### What does Rapid Micro actually sell to drug manufacturers? Rapid Micro describes itself as a life sciences technology company focused on microbiology quality control. In its earnings release, the company said its automation products are designed to support the efficient manufacturing and “fast, safe release of healthcare products” in regulated settings. (sec.gov) The Growth Direct platform is the center of that pitch. Management said customer discussions are increasingly extending beyond single-system purchases to company-wide automation strategies and broader integration of the platform. (sec.gov) ### Which parts of the business grew, and which did not? Product revenue increased to $5.6 million from $4.1 million in the year-earlier quarter, Rapid Micro said. Service revenue moved the other way, falling 21.9% to $2.4 million from $3.1 million. The company said the decline was primarily due to lower validation activity in the quarter compared with the prior year. (sec.gov) Recurring revenue rose to $5.1 million from $4.0 million. Rapid Micro said that category includes revenue tied to its installed base, and management linked the increase to consumables demand and utilization trends. (sec.gov) ### Did margins improve with the higher revenue? Gross margin was 4.6%, or about $0.4 million, in the first quarter of 2026, compared with 5.6%, or about $0.4 million, in the first quarter of 2025, the company said. Total cost of revenue increased 12.2% to $7.6 million, while operating expenses rose 17.9% to $14.2 million from $12.1 million. (sec.gov) The company separately highlighted improvement in product and consumable gross margin percentages. In the bullet-point summary of the release, Rapid Micro said product gross margin percentage increased 15 percentage points and consumable gross margin increased 33 percentage points. (sec.gov) ### What did management say about partnerships and the rest of 2026? MilliporeSigma was named in one of the few strategic updates in the release. Rapid Micro said it had advanced that collaboration through the execution of a services agreement. For the rest of 2026, the company reaffirmed guidance for total revenue of $37.0 million to $41.0 million, approximately 20% gross margin for the year, and a fourth-quarter 2026 exit rate in the mid-20% range. (sec.gov) Rapid Micro also said investors can find an updated corporate presentation on its investor relations website, and the company’s annual meeting is scheduled for May 21, 2026. (biospace.com)